Clinical trials supporting their approval typically lasted 68 to 72 weeks, but extension studies have followed patients for longer periods
What began as a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes (Ozempic, approved 2017) has evolved into a multi-formulation, multi-indication therapeutic platform with three commercially marketed products: Ozempic (injectable, diabetes + cardiovascular + CKD), Wegovy (injectable, obesity + cardiovascular + MASH), and Rybelsus (oral tablet, diabetes + cardiovascular + obesity)
But if you are in perimenopause, menopause, or postmenopause and your main concern is midlife weight change, you may want to compare Brello against providers that speak more directly to: Hormonal weight changes Belly fat and body composition shifts Muscle loss and strength training Sleep issues Menopause symptoms HRT-adjacent care Long-term maintenance Nutrition for women over 35 or 40 Research has found that menopause is associated with changes in body composition, including increased abdominal or visceral fat, and Mayo Clinic notes that many women find it harder to maintain their usual weight around perimenopause and menopause
Aim the needle at the vial wall, not directly at the peptide powder
Common signs include chronic fatigue, frequent illness, slow recovery, brain fog, increased sensitivity to chemicals or medications, skin issues, and chronic inflammation
